z-logo
Premium
Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus
Author(s) -
Piccinni MP,
Lombardelli L,
Logiodice F,
Tesi D,
Kullolli O,
Biagiotti R,
Giudizi MG,
Romagnani S,
Maggi E,
Ficarra G
Publication year - 2014
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12094
Subject(s) - oral lichen planus , rar related orphan receptor gamma , reticular connective tissue , interleukin 17 , oral mucosa , pathogenesis , pathology , foxp3 , immunology , biology , medicine , cytokine , immune system
Objectives The role of Th17 cells and associated cytokines was investigated in oral lichen planus. Material and methods 14 consecutive patients with oral lichen planus were investigated. For biological studies, tissues were taken from reticular or erosive lesions and from normal oral mucosa (controls) of the same patient. mRNA expression for IL‐17F, IL‐17A, MCP‐1, IL‐13, IL‐2, IL‐10, IL‐1β, RANTES, IL‐4, IL‐12B, IL‐8, IFN‐γ, TNF‐α, IL‐1α, IL‐18, TGF‐β1, IL‐23R, IL‐7, IL‐15, IL‐6, MIG, IP‐10, LTB, VEGF, IL‐5, IL‐27, IL‐23A, GAPDH, PPIB, Foxp3, GATA3, and RORC was measured using the QuantiGene 2.0. Results Results showed that Th17‐type and Th0‐type molecules' mRNA s, when compared with results obtained from tissue controls, were increased in biopsies of erosive lesions, whereas Th2‐type molecules' mRNA s were increased in reticular lesions. When the CD4+ T‐cell clones, derived from oral lichen planus tissues and tissue controls, were analyzed, a higher prevalence of Th17 (confirmed by an increased CD161 expression) and Th0 CD4+ T clones was found in erosive lesions, whereas a prevalence of Th2 clones was observed in reticular lesions. Conclusions Our data suggest that Th17, Th0, and Th2 cells, respectively, may have a role in the pathogenesis of erosive and reticular oral lichen planus.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here